

# Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Growth 2024-2030

<https://marketpublishers.com/r/GF62BD518FBAEN.html>

Date: November 2024

Pages: 128

Price: US\$ 3,660.00 (Single User License)

ID: GF62BD518FBAEN

## Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

TNF inhibitors are a class of biologic medications used in the treatment of plaque psoriasis, a common form of the disease characterized by raised, red patches covered with a silvery white buildup of dead skin cells. By blocking TNF-alpha, these drugs help reduce inflammation and slow down the excessive growth of skin cells that cause plaques.

The global TNF Inhibitors for the Treatment of Plaque Psoriasis market size is projected to grow from US\$ million in 2024 to US\$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the "TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Forecast" looks at past sales and reviews total world TNF Inhibitors for the Treatment of Plaque Psoriasis sales in 2023, providing a comprehensive analysis by region and market sector of projected TNF Inhibitors for the Treatment of Plaque Psoriasis sales for 2024 through 2030. With TNF Inhibitors for the Treatment of Plaque Psoriasis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world TNF Inhibitors for the Treatment of Plaque Psoriasis industry.

This Insight Report provides a comprehensive analysis of the global TNF Inhibitors for the Treatment of Plaque Psoriasis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on TNF Inhibitors for the Treatment of Plaque Psoriasis

portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global TNF Inhibitors for the Treatment of Plaque Psoriasis market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for TNF Inhibitors for the Treatment of Plaque Psoriasis and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global TNF Inhibitors for the Treatment of Plaque Psoriasis.

United States market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key TNF Inhibitors for the Treatment of Plaque Psoriasis players cover Amgen, AbbVie, Janssen Biotech, Pfizer, Samsung Bioepis, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of TNF Inhibitors for the Treatment of Plaque Psoriasis market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Etanercept

Infliximab

Adalimumab

Certolizumab pegol

Other

Segmentation by Application:

Hospital and Clinic

Retail Pharmacies

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Amgen

AbbVie

Janssen Biotech

Pfizer

Samsung Bioepis

UCB

Sandoz

Boehringer Ingelheim Pharmaceuticals

Biocon Biologics

Coherus BioSciences

YL Biologics

Celltrion

Teva

Innovent Biologics

Bio-Thera Solutions

Sino Cell Technologies

Hangzhou Bozhirui Biopharmaceuticals

Chia Tai Tianqing Pharmaceutical

Hisun Pharmaceuticals

## Key Questions Addressed in this Report

What is the 10-year outlook for the global TNF Inhibitors for the Treatment of Plaque Psoriasis market?

What factors are driving TNF Inhibitors for the Treatment of Plaque Psoriasis market

growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do TNF Inhibitors for the Treatment of Plaque Psoriasis market opportunities vary by end market size?

How does TNF Inhibitors for the Treatment of Plaque Psoriasis break out by Type, by Application?

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

### 2 EXECUTIVE SUMMARY

#### 2.1 World Market Overview

- 2.1.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Sales 2019-2030

- 2.1.2 World Current & Future Analysis for TNF Inhibitors for the Treatment of Plaque Psoriasis by Geographic Region, 2019, 2023 & 2030

- 2.1.3 World Current & Future Analysis for TNF Inhibitors for the Treatment of Plaque Psoriasis by Country/Region, 2019, 2023 & 2030

#### 2.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Type

- 2.2.1 Etanercept

- 2.2.2 Infliximab

- 2.2.3 Adalimumab

- 2.2.4 Certolizumab pegol

- 2.2.5 Other

#### 2.3 TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type

- 2.3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Type (2019-2024)

- 2.3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue and Market Share by Type (2019-2024)

- 2.3.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sale Price by Type (2019-2024)

#### 2.4 TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Application

- 2.4.1 Hospital and Clinic

- 2.4.2 Retail Pharmacies

- 2.4.3 Other

## 2.5 TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application

2.5.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sale Market Share by Application (2019-2024)

2.5.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue and Market Share by Application (2019-2024)

2.5.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sale Price by Application (2019-2024)

## 3 GLOBAL BY COMPANY

3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Breakdown Data by Company

3.1.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Sales by Company (2019-2024)

3.1.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Company (2019-2024)

3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Revenue by Company (2019-2024)

3.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Company (2019-2024)

3.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Company (2019-2024)

3.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sale Price by Company

3.4 Key Manufacturers TNF Inhibitors for the Treatment of Plaque Psoriasis Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers TNF Inhibitors for the Treatment of Plaque Psoriasis Product Location Distribution

3.4.2 Players TNF Inhibitors for the Treatment of Plaque Psoriasis Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

## 4 WORLD HISTORIC REVIEW FOR TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS BY GEOGRAPHIC REGION

4.1 World Historic TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Geographic Region (2019-2024)



4.1.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Sales by Geographic Region (2019-2024)

4.1.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Revenue by Geographic Region (2019-2024)

4.2 World Historic TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Country/Region (2019-2024)

4.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Sales by Country/Region (2019-2024)

4.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Revenue by Country/Region (2019-2024)

4.3 Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth

4.4 APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth

4.5 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth

4.6 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth

## **5 AMERICAS**

5.1 Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country

5.1.1 Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2019-2024)

5.1.2 Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2019-2024)

5.2 Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2019-2024)

5.3 Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2019-2024)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

## **6 APAC**

6.1 APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region

6.1.1 APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region (2019-2024)

6.1.2 APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region (2019-2024)

6.2 APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2019-2024)

6.3 APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2019-2024)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

## **7 EUROPE**

7.1 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis by Country

7.1.1 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2019-2024)

7.1.2 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2019-2024)

7.2 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2019-2024)

7.3 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2019-2024)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

## **8 MIDDLE EAST & AFRICA**

8.1 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis by Country

8.1.1 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2019-2024)

8.1.2 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Country (2019-2024)

8.2 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2019-2024)

8.3 Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2019-2024)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

## **9 MARKET DRIVERS, CHALLENGES AND TRENDS**

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

## **10 MANUFACTURING COST STRUCTURE ANALYSIS**

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of TNF Inhibitors for the Treatment of Plaque Psoriasis

10.3 Manufacturing Process Analysis of TNF Inhibitors for the Treatment of Plaque Psoriasis

10.4 Industry Chain Structure of TNF Inhibitors for the Treatment of Plaque Psoriasis

## **11 MARKETING, DISTRIBUTORS AND CUSTOMER**

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Distributors

11.3 TNF Inhibitors for the Treatment of Plaque Psoriasis Customer

## **12 WORLD FORECAST REVIEW FOR TNF INHIBITORS FOR THE TREATMENT OF PLAQUE PSORIASIS BY GEOGRAPHIC REGION**

12.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size Forecast by Region

12.1.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Forecast by Region (2025-2030)

12.1.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Revenue

Forecast by Region (2025-2030)

12.2 Americas Forecast by Country (2025-2030)

12.3 APAC Forecast by Region (2025-2030)

12.4 Europe Forecast by Country (2025-2030)

12.5 Middle East & Africa Forecast by Country (2025-2030)

12.6 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Forecast by Type (2025-2030)

12.7 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Forecast by Application (2025-2030)

## **13 KEY PLAYERS ANALYSIS**

13.1 Amgen

13.1.1 Amgen Company Information

13.1.2 Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

13.1.3 Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.1.4 Amgen Main Business Overview

13.1.5 Amgen Latest Developments

13.2 AbbVie

13.2.1 AbbVie Company Information

13.2.2 AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

13.2.3 AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.2.4 AbbVie Main Business Overview

13.2.5 AbbVie Latest Developments

13.3 Janssen Biotech

13.3.1 Janssen Biotech Company Information

13.3.2 Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

13.3.3 Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.3.4 Janssen Biotech Main Business Overview

13.3.5 Janssen Biotech Latest Developments

13.4 Pfizer

13.4.1 Pfizer Company Information

13.4.2 Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios

## and Specifications

13.4.3 Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.4.4 Pfizer Main Business Overview

13.4.5 Pfizer Latest Developments

## 13.5 Samsung Bioepis

13.5.1 Samsung Bioepis Company Information

13.5.2 Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

13.5.3 Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.5.4 Samsung Bioepis Main Business Overview

13.5.5 Samsung Bioepis Latest Developments

## 13.6 UCB

13.6.1 UCB Company Information

13.6.2 UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

13.6.3 UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.6.4 UCB Main Business Overview

13.6.5 UCB Latest Developments

## 13.7 Sandoz

13.7.1 Sandoz Company Information

13.7.2 Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

13.7.3 Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.7.4 Sandoz Main Business Overview

13.7.5 Sandoz Latest Developments

## 13.8 Boehringer Ingelheim Pharmaceuticals

13.8.1 Boehringer Ingelheim Pharmaceuticals Company Information

13.8.2 Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

13.8.3 Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.8.4 Boehringer Ingelheim Pharmaceuticals Main Business Overview

13.8.5 Boehringer Ingelheim Pharmaceuticals Latest Developments

## 13.9 Biocon Biologics

13.9.1 Biocon Biologics Company Information

13.9.2 Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

13.9.3 Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.9.4 Biocon Biologics Main Business Overview

13.9.5 Biocon Biologics Latest Developments

13.10 Coherus BioSciences

13.10.1 Coherus BioSciences Company Information

13.10.2 Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

13.10.3 Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.10.4 Coherus BioSciences Main Business Overview

13.10.5 Coherus BioSciences Latest Developments

13.11 YL Biologics

13.11.1 YL Biologics Company Information

13.11.2 YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

13.11.3 YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.11.4 YL Biologics Main Business Overview

13.11.5 YL Biologics Latest Developments

13.12 Celltrion

13.12.1 Celltrion Company Information

13.12.2 Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

13.12.3 Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.12.4 Celltrion Main Business Overview

13.12.5 Celltrion Latest Developments

13.13 Teva

13.13.1 Teva Company Information

13.13.2 Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

13.13.3 Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

13.13.4 Teva Main Business Overview

13.13.5 Teva Latest Developments

13.14 Innovent Biologics

- 13.14.1 Innovent Biologics Company Information
- 13.14.2 Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
- 13.14.3 Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.14.4 Innovent Biologics Main Business Overview
- 13.14.5 Innovent Biologics Latest Developments
- 13.15 Bio-Thera Solutions
  - 13.15.1 Bio-Thera Solutions Company Information
  - 13.15.2 Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
  - 13.15.3 Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
  - 13.15.4 Bio-Thera Solutions Main Business Overview
  - 13.15.5 Bio-Thera Solutions Latest Developments
- 13.16 Sino Cell Technologies
  - 13.16.1 Sino Cell Technologies Company Information
  - 13.16.2 Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
  - 13.16.3 Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
  - 13.16.4 Sino Cell Technologies Main Business Overview
  - 13.16.5 Sino Cell Technologies Latest Developments
- 13.17 Hangzhou Bozhirui Biopharmaceuticals
  - 13.17.1 Hangzhou Bozhirui Biopharmaceuticals Company Information
  - 13.17.2 Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
  - 13.17.3 Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
  - 13.17.4 Hangzhou Bozhirui Biopharmaceuticals Main Business Overview
  - 13.17.5 Hangzhou Bozhirui Biopharmaceuticals Latest Developments
- 13.18 Chia Tai Tianqing Pharmaceutical
  - 13.18.1 Chia Tai Tianqing Pharmaceutical Company Information
  - 13.18.2 Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
  - 13.18.3 Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)
  - 13.18.4 Chia Tai Tianqing Pharmaceutical Main Business Overview
  - 13.18.5 Chia Tai Tianqing Pharmaceutical Latest Developments



### 13.19 Hisun Pharmaceuticals

#### 13.19.1 Hisun Pharmaceuticals Company Information

#### 13.19.2 Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

#### 13.19.3 Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2019-2024)

#### 13.19.4 Hisun Pharmaceuticals Main Business Overview

#### 13.19.5 Hisun Pharmaceuticals Latest Developments

## 14 RESEARCH FINDINGS AND CONCLUSION

### LIST OF TABLES

Table 1. TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Table 2. TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)

Table 3. Major Players of Etanercept

Table 4. Major Players of Infliximab

Table 5. Major Players of Adalimumab

Table 6. Major Players of Certolizumab pegol

Table 7. Major Players of Other

Table 8. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2019-2024) & (K Units)

Table 9. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Type (2019-2024)

Table 10. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2019-2024) & (\$ million)

Table 11. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Type (2019-2024)

Table 12. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sale Price by Type (2019-2024) & (US\$/Unit)

Table 13. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sale by Application (2019-2024) & (K Units)

Table 14. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sale Market Share by Application (2019-2024)

Table 15. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2019-2024) & (\$ million)



Table 16. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Application (2019-2024)

Table 17. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sale Price by Application (2019-2024) & (US\$/Unit)

Table 18. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Company (2019-2024) & (K Units)

Table 19. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Company (2019-2024)

Table 20. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Company (2019-2024) & (\$ millions)

Table 21. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Company (2019-2024)

Table 22. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sale Price by Company (2019-2024) & (US\$/Unit)

Table 23. Key ManufacturersTNF Inhibitors for theTreatment of Plaque Psoriasis Producing Area Distribution and Sales Area

Table 24. PlayersTNF Inhibitors for theTreatment of Plaque Psoriasis Products Offered

Table 25. TNF Inhibitors for theTreatment of Plaque Psoriasis Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 26. New Products and Potential Entrants

Table 27. Market M&A Activity & Strategy

Table 28. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Geographic Region (2019-2024) & (K Units)

Table 29. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share Geographic Region (2019-2024)

Table 30. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Geographic Region (2019-2024) & (\$ millions)

Table 31. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Geographic Region (2019-2024)

Table 32. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Country/Region (2019-2024) & (K Units)

Table 33. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Country/Region (2019-2024)

Table 34. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Country/Region (2019-2024) & (\$ millions)

Table 35. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Country/Region (2019-2024)

Table 36. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Country (2019-2024) & (K Units)

Table 37. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Country (2019-2024)

Table 38. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Country (2019-2024) & (\$ millions)

Table 39. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Sales byType (2019-2024) & (K Units)

Table 40. AmericasTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Application (2019-2024) & (K Units)

Table 41. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Region (2019-2024) & (K Units)

Table 42. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Region (2019-2024)

Table 43. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Region (2019-2024) & (\$ millions)

Table 44. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales byType (2019-2024) & (K Units)

Table 45. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Application (2019-2024) & (K Units)

Table 46. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Country (2019-2024) & (K Units)

Table 47. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue by Country (2019-2024) & (\$ millions)

Table 48. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Sales byType (2019-2024) & (K Units)

Table 49. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Application (2019-2024) & (K Units)

Table 50. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Country (2019-2024) & (K Units)

Table 51. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Country (2019-2024)

Table 52. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Sales byType (2019-2024) & (K Units)

Table 53. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Application (2019-2024) & (K Units)

Table 54. Key Market Drivers & Growth Opportunities ofTNF Inhibitors for theTreatment of Plaque Psoriasis

Table 55. Key Market Challenges & Risks ofTNF Inhibitors for theTreatment of Plaque Psoriasis

Table 56. Key IndustryTrends ofTNF Inhibitors for theTreatment of Plaque Psoriasis

- Table 57. TNF Inhibitors for the Treatment of Plaque Psoriasis Raw Material
- Table 58. Key Suppliers of Raw Materials
- Table 59. TNF Inhibitors for the Treatment of Plaque Psoriasis Distributors List
- Table 60. TNF Inhibitors for the Treatment of Plaque Psoriasis Customer List
- Table 61. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Forecast by Region (2025-2030) & (K Units)
- Table 62. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Forecast by Region (2025-2030) & (\$ millions)
- Table 63. Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Forecast by Country (2025-2030) & (K Units)
- Table 64. Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Revenue Forecast by Country (2025-2030) & (\$ millions)
- Table 65. APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Forecast by Region (2025-2030) & (K Units)
- Table 66. APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Annual Revenue Forecast by Region (2025-2030) & (\$ millions)
- Table 67. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Forecast by Country (2025-2030) & (K Units)
- Table 68. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Forecast by Country (2025-2030) & (\$ millions)
- Table 69. Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Forecast by Country (2025-2030) & (K Units)
- Table 70. Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Forecast by Country (2025-2030) & (\$ millions)
- Table 71. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Forecast by Type (2025-2030) & (K Units)
- Table 72. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Forecast by Type (2025-2030) & (\$ millions)
- Table 73. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Forecast by Application (2025-2030) & (K Units)
- Table 74. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Forecast by Application (2025-2030) & (\$ millions)
- Table 75. Amgen Basic Information, TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors
- Table 76. Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications
- Table 77. Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 78. Amgen Main Business

Table 79. Amgen Latest Developments

Table 80. AbbVie Basic Information, TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 81. AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

Table 82. AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 83. AbbVie Main Business

Table 84. AbbVie Latest Developments

Table 85. Janssen Biotech Basic Information, TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 86. Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

Table 87. Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 88. Janssen Biotech Main Business

Table 89. Janssen Biotech Latest Developments

Table 90. Pfizer Basic Information, TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 91. Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

Table 92. Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 93. Pfizer Main Business

Table 94. Pfizer Latest Developments

Table 95. Samsung Bioepis Basic Information, TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 96. Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

Table 97. Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 98. Samsung Bioepis Main Business

Table 99. Samsung Bioepis Latest Developments

Table 100. UCB Basic Information, TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 101. UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

Table 102. UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 103. UCB Main Business

Table 104. UCB Latest Developments

Table 105. Sandoz Basic Information, TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 106. Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

Table 107. Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 108. Sandoz Main Business

Table 109. Sandoz Latest Developments

Table 110. Boehringer Ingelheim Pharmaceuticals Basic Information, TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 111. Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

Table 112. Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 113. Boehringer Ingelheim Pharmaceuticals Main Business

Table 114. Boehringer Ingelheim Pharmaceuticals Latest Developments

Table 115. Biocon Biologics Basic Information, TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 116. Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

Table 117. Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 118. Biocon Biologics Main Business

Table 119. Biocon Biologics Latest Developments

Table 120. Coherus BioSciences Basic Information, TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 121. Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

Table 122. Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 123. Coherus BioSciences Main Business

Table 124. Coherus BioSciences Latest Developments

Table 125. YL Biologics Basic Information, TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 126. YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications



Table 127. YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 128. YL Biologics Main Business

Table 129. YL Biologics Latest Developments

Table 130. Celltrion Basic Information, TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 131. Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

Table 132. Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 133. Celltrion Main Business

Table 134. Celltrion Latest Developments

Table 135. Teva Basic Information, TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 136. Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

Table 137. Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 138. Teva Main Business

Table 139. Teva Latest Developments

Table 140. Innovent Biologics Basic Information, TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 141. Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

Table 142. Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 143. Innovent Biologics Main Business

Table 144. Innovent Biologics Latest Developments

Table 145. Bio-Thera Solutions Basic Information, TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 146. Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolios and Specifications

Table 147. Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 148. Bio-Thera Solutions Main Business

Table 149. Bio-Thera Solutions Latest Developments

Table 150. Sino Cell Technologies Basic Information, TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 151. Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis

## Product Portfolios and Specifications

Table 152. Sino CellTechnologiesTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 153. Sino CellTechnologies Main Business

Table 154. Sino CellTechnologies Latest Developments

Table 155. Hangzhou Bozhirui Biopharmaceuticals Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 156. Hangzhou Bozhirui BiopharmaceuticalsTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications

Table 157. Hangzhou Bozhirui BiopharmaceuticalsTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 158. Hangzhou Bozhirui Biopharmaceuticals Main Business

Table 159. Hangzhou Bozhirui Biopharmaceuticals Latest Developments

Table 160. ChiaTaiTianqing Pharmaceutical Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 161. ChiaTaiTianqing PharmaceuticalTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications

Table 162. ChiaTaiTianqing PharmaceuticalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 163. ChiaTaiTianqing Pharmaceutical Main Business

Table 164. ChiaTaiTianqing Pharmaceutical Latest Developments

Table 165. Hisun Pharmaceuticals Basic Information,TNF Inhibitors for theTreatment of Plaque Psoriasis Manufacturing Base, Sales Area and Its Competitors

Table 166. Hisun PharmaceuticalsTNF Inhibitors for theTreatment of Plaque Psoriasis Product Portfolios and Specifications

Table 167. Hisun PharmaceuticalsTNF Inhibitors for theTreatment of Plaque Psoriasis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 168. Hisun Pharmaceuticals Main Business

Table 169. Hisun Pharmaceuticals Latest Developments

## LIST OFFIGURES

Figure 1. Picture ofTNF Inhibitors for theTreatment of Plaque Psoriasis

Figure 2.TNF Inhibitors for theTreatment of Plaque Psoriasis Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Growth Rate 2019-2030 (K Units)

Figure 7. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth Rate 2019-2030 (\$ millions)

Figure 8.TNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Figure 9.TNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Country/Region (2023)

Figure 10.TNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Country/Region (2019, 2023 & 2030)

Figure 11. Product Picture of Etanercept

Figure 12. Product Picture of Infliximab

Figure 13. Product Picture of Adalimumab

Figure 14. Product Picture of Certolizumab pegol

Figure 15. Product Picture of Other

Figure 16. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share byType in 2023

Figure 17. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share byType (2019-2024)

Figure 18.TNF Inhibitors for theTreatment of Plaque Psoriasis Consumed in Hospital and Clinic

Figure 19. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Market: Hospital and Clinic (2019-2024) & (K Units)

Figure 20.TNF Inhibitors for theTreatment of Plaque Psoriasis Consumed in Retail Pharmacies

Figure 21. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Market: Retail Pharmacies (2019-2024) & (K Units)

Figure 22.TNF Inhibitors for theTreatment of Plaque Psoriasis Consumed in Other

Figure 23. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Market: Other (2019-2024) & (K Units)

Figure 24. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sale Market Share by Application (2023)

Figure 25. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Application in 2023

Figure 26.TNF Inhibitors for theTreatment of Plaque Psoriasis Sales by Company in 2023 (K Units)

Figure 27. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market



Share by Company in 2023

Figure 28. TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Company in 2023 (\$ millions)

Figure 29. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Company in 2023

Figure 30. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Geographic Region (2019-2024)

Figure 31. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Geographic Region in 2023

Figure 32. Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Sales 2019-2024 (K Units)

Figure 33. Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue 2019-2024 (\$ millions)

Figure 34. APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Sales 2019-2024 (K Units)

Figure 35. APAC TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue 2019-2024 (\$ millions)

Figure 36. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales 2019-2024 (K Units)

Figure 37. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue 2019-2024 (\$ millions)

Figure 38. Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales 2019-2024 (K Units)

Figure 39. Middle East & Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue 2019-2024 (\$ millions)

Figure 40. Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Country in 2023

Figure 41. Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Country (2019-2024)

Figure 42. Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Type (2019-2024)

Figure 43. Americas TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Application (2019-2024)

Figure 44. United States TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 45. Canada TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 46. Mexico TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 47. BrazilTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 48. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Region in 2023

Figure 49. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Region (2019-2024)

Figure 50. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share byType (2019-2024)

Figure 51. APACTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Application (2019-2024)

Figure 52. ChinaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 53. JapanTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 54. South KoreaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 55. Southeast AsiaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 56. IndiaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 57. AustraliaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 58. ChinaTaiwanTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 59. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Country in 2023

Figure 60. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market Share by Country (2019-2024)

Figure 61. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share byType (2019-2024)

Figure 62. EuropeTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market Share by Application (2019-2024)

Figure 63. GermanyTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 64. FranceTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 65. UKTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth 2019-2024 (\$ millions)

Figure 66. ItalyTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth

2019-2024 (\$ millions)

Figure 67. RussiaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth

2019-2024 (\$ millions)

Figure 68. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis

Sales Market Share by Country (2019-2024)

Figure 69. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis

Sales Market Share byType (2019-2024)

Figure 70. Middle East & AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis

Sales Market Share by Application (2019-2024)

Figure 71. EgyptTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth

2019-2024 (\$ millions)

Figure 72. South AfricaTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue

Growth 2019-2024 (\$ millions)

Figure 73. IsraelTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth

2019-2024 (\$ millions)

Figure 74. TurkeyTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Growth

2019-2024 (\$ millions)

Figure 75. GCC CountriesTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue

Growth 2019-2024 (\$ millions)

Figure 76. Manufacturing Cost Structure Analysis ofTNF Inhibitors for theTreatment of

Plaque Psoriasis in 2023

Figure 77. Manufacturing Process Analysis ofTNF Inhibitors for theTreatment of Plaque

Psoriasis

Figure 78. Industry Chain Structure ofTNF Inhibitors for theTreatment of Plaque

Psoriasis

Figure 79. Channels of Distribution

Figure 80. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales

MarketForecast by Region (2025-2030)

Figure 81. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market

ShareForecast by Region (2025-2030)

Figure 82. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market

ShareForecast byType (2025-2030)

Figure 83. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market

ShareForecast byType (2025-2030)

Figure 84. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Sales Market

ShareForecast by Application (2025-2030)

Figure 85. GlobalTNF Inhibitors for theTreatment of Plaque Psoriasis Revenue Market

ShareForecast by Application (2025-2030)

## I would like to order

Product name: Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/GF62BD518FBAEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF62BD518FBAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970